Premium
TNF ‐α antagonist may not be suitable for severe rituximab‐induced interstitial lung disease
Author(s) -
Tan J.,
Ni X.
Publication year - 2015
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12252
Subject(s) - rituximab , interstitial lung disease , medicine , antagonist , lung , pharmacology , lymphoma , receptor
Summary What is known and Objective Rituximab‐induced interstitial lung disease (R‐ ILD ) has aroused more concern in recent years. Anti‐ TNF ‐α treatment has been suggested for the treatment of severe R‐ ILD , due to the plausible suggestion that its pathogenesis is related to TNF ‐α. This commentary aimed to comment on the role of TNF ‐α antagonists in R‐ ILD . Comment Although most R‐ ILD patients respond well to glucocorticoids, other treatment options are needed for patients who are refractory to conventional treatment. Contrary to expectations, the TNF ‐α antagonist etanercept brought no benefit in R‐ ILD . Moreover, TNF ‐α‐targeted therapies were reported to induce or exacerbate interstitial lung disease. What is new and conclusion The role of TNF ‐α in the pathogenesis of R‐ ILD is still unclear due to limited studies on its aetiology. Use of TNF ‐α antagonists in R‐ ILD is still speculative, as clinical trials do not support its efficacy. What's more, TNF ‐α antagonists may themselves induce interstitial lung disease with poor prognosis.